JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Elenco Azioni・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Chiusa

1.14 4.59

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.1400000000000001

Massimo

1.15

Metriche Chiave
By Trading Economics
Entrata	17M -26M
Dipendenti	171
EBITDA	19M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Vendi
Previsioni per 12 mesi	+266.97% upside

Dividendi
By Dow Jones
Utili prossimi	26 feb 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-29M 73M
Apertura precedente	-3.45
Chiusura precedente	1.14

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

1.43 / 1.6 Supporto e resistenza

Pliant Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Acquisizioni, Fusioni, Takeovers

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Discorsi di Mercato

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Utili

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Utili

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Utili

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Discorsi di Mercato

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Utili

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6 feb 2026, 20:27 UTC

Utili

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6 feb 2026, 20:24 UTC

Discorsi di Mercato

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6 feb 2026, 20:20 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6 feb 2026, 19:48 UTC

Utili

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6 feb 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6 feb 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6 feb 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6 feb 2026, 19:17 UTC

Discorsi di Mercato

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6 feb 2026, 18:50 UTC

Utili

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 18:47 UTC

Discorsi di Mercato

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6 feb 2026, 18:34 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6 feb 2026, 17:58 UTC

Utili

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6 feb 2026, 17:52 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

6 feb 2026, 17:52 UTC

Discorsi di Mercato

Utili

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6 feb 2026, 17:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

6 feb 2026, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

6 feb 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 feb 2026, 17:18 UTC

Discorsi di Mercato

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6 feb 2026, 17:09 UTC

Discorsi di Mercato

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Confronto tra pari

Modifica del prezzo

Pliant Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

266.97% in crescita

Previsioni per 12 mesi

Media 4 USD 266.97%

Alto 4 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pliant Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Pliant Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.43 / 1.6Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.